PacBio Beefs Up with Purchase of Omniome for $800 Million

FORWARD-LOOKING PATHOLOGISTS AND LAB ADMINISTRATORS understand that the next big game in medical laboratory testing will be assays built upon genome sequencing. They also know that several companies are racing to produce gene sequencing instruments that are faster, simpler, and less costly in order to serve the needs of clinical labs. Currently, Illumina, Inc., of …

PacBio Beefs Up with Purchase of Omniome for $800 Million Read More »

To access this post, you must purchase The Dark Report.

PacBio Beefs Up with Purchase of Omniome for $800 Million

Gene sequencing company will have both long-read and short-read DNA sequencing

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month